Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time

DexCom plans to release its third-quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will review the results on a concurrently webcast conference call beginning at 4:30 p.m. Eastern Time.

Analysis

This is a calendar notice, not a change in DexCom’s earnings outlook; it provides no directional edge on DXCM. With the report several weeks away, the near-term effect is likely limited to attention shifting toward the event and, closer to release, potential repricing of earnings volatility. The substantive read-through will be whether reported growth and forward guidance support expectations for CGM adoption and whether competition, pricing, or reimbursement conditions are affecting the outlook. Those details are not provided here and should be verified against the release and call rather than inferred from the announcement. Any read-through to Abbott should be based on comparative CGM performance, not assumed market-share movement. The event thesis weakens if options do not show unusual implied volatility or if the report yields no material change to guidance; a meaningful outlook revision would be the key catalyst.

Key Decisions for Investors

• No directional DXCM position on this notice alone; it contains no financial results or updated guidance.
• Track DXCM options implied volatility and skew as October 29 approaches. Consider an event-volatility trade only if pricing is attractive relative to realized moves and the expected move; avoid assuming that a scheduled call implies a volatility opportunity.
• Before taking a directional view, verify quarterly growth, forward guidance, and management commentary on pricing, reimbursement, and competitive conditions; compare relevant CGM disclosures from Abbott for corroboration.
• Falsify a bullish post-earnings thesis if guidance or growth commentary deteriorates; falsify a bearish thesis if results and guidance hold up without evidence of worsening competitive or reimbursement pressure.